Melanoma antibodies

and ELISA kits, proteins related to Melanoma.

Introduction to Melanoma

**Understanding Melanoma** Melanoma is a serious and aggressive form of skin cancer that originates in melanocytes, the cells responsible for producing the pigment melanin. Unlike other skin cancers, melanoma is more likely to grow and spread to other parts of the body if not detected early. It can develop anywhere on the skin, including areas not typically exposed to the sun, such as the eyes and internal organs. Advances in melanoma research have focused on harnessing antibodies to target cancer cells more precisely, improving treatment efficacy and reducing side effects. These antibody-based therapies work by enhancing the immune system's ability to recognize and eliminate malignant cells. Ongoing research is critical in the fight against melanoma, offering hope for more effective and personalized treatment options that can significantly improve patient outcomes.

Melanoma biomarkers

PB9385

Anti-PTEN Antibody Picoband®, PTEN/PI3K/Akt pathway’s contribution in miR-21 induced proliferation in c-kit + CSCs. Cultured c-kit + CSCs were treated with miR-21 mimics for 48...

M00979-1

Anti-S100B/S100 Beta Rabbit Monoclonal Antibody, IF analysis of S100B using anti-S100B antibody (M00979-1) .
S100B was detected in an immunocytochemical section of rat C6...

M00099-1

Anti-KRAS+HRAS+NRAS Rabbit Monoclonal Antibody, Immunofluorescent analysis of Hela cells, using KRAS+HRAS+NRAS Antibody....

Protein Name	Gene Name	Function
BRAF	BRAF	Kinase involved in cell growth signaling
NRAS	NRAS	GTPase involved in cell signaling pathways
KIT	KIT	Receptor tyrosine kinase involved in cell survival
PD-L1	CD274	Immune checkpoint protein that inhibits T-cell function
S100B	S100B	Calcium-binding protein involved in cell cycle progression
MITF	MITF	Transcription factor important for melanocyte development
CDKN2A	CDKN2A	Tumor suppressor regulating cell cycle
PTEN	PTEN	Tumor suppressor involved in cell growth regulation
MIA	MIA	Melanoma inhibitory activity protein involved in tumor progression
SOX10	SOX10	Transcription factor in neural crest development
p53	TP53	Tumor suppressor regulating cell division and apoptosis
VEGF	VEGFA	Angiogenic factor promoting blood vessel formation
CXCR4	CXCR4	Chemokine receptor involved in metastasis
EGFR	EGFR	Receptor tyrosine kinase involved in cell growth and differentiation
ALK	ALK	Receptor tyrosine kinase implicated in cell proliferation
CD271	NGFR	Nerve growth factor receptor involved in cell survival
HIF-1α	HIF1A	Transcription factor responding to hypoxia
Melan-A	MLANA	Protein involved in melanocyte differentiation
Galectin-3	LGALS3	Protein involved in cell adhesion and metastasis
TYR	TYR	Enzyme involved in melanin biosynthesis

Important Mechanisms

Immunotherapy and the Tumor Microenvironment

Immunotherapy has revolutionized the treatment landscape for melanoma by harnessing the body’s immune system to recognize and eliminate cancer cells. This sub-area focuses on understanding the interactions between melanoma cells and the immune system, particularly within the tumor microenvironment. Key advancements include the development of immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, which have shown significant efficacy in improving patient survival. Researchers are also exploring combination therapies that enhance immune response and overcome resistance mechanisms. Additionally, studies on tumor-infiltrating lymphocytes (TILs) and the role of cytokines contribute to optimizing immunotherapeutic strategies. Understanding the dynamics of the tumor microenvironment, including factors like immune cell infiltration, cytokine milieu, and checkpoint molecule expression, is critical for identifying biomarkers that predict response to immunotherapy and for developing personalized treatment approaches. Ongoing research aims to mitigate immune-related adverse effects and to expand the applicability of immunotherapy to a broader range of melanoma patients.

Targeted Molecular Therapies

Targeted molecular therapies represent a pivotal area of melanoma research, focusing on identifying and inhibating specific genetic mutations and signaling pathways that drive melanoma progression. One of the most significant breakthroughs in this field has been the discovery of BRAF mutations, present in approximately 50% of melanoma cases. Inhibitors targeting the BRAF V600E mutation, such as vemurafenib and dabrafenib, have demonstrated substantial clinical benefits. Additionally, MEK inhibitors like trametinib are used in combination with BRAF inhibitors to enhance therapeutic efficacy and delay resistance. Beyond the BRAF-MEK axis, research is expanding into other molecular targets, including NRAS mutations, c-KIT alterations, and the PI3K/AKT/mTOR pathway. The development of resistance to targeted therapies remains a major challenge, prompting investigations into combination treatments and novel inhibitors. Personalized medicine approaches, guided by comprehensive genomic profiling, enable the selection of appropriate targeted agents based on individual tumor profiles. This sub-area continues to evolve rapidly, aiming to improve outcomes and extend survival for melanoma patients through precision-based therapeutic interventions.